Back to Search
Start Over
An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON)
- Source :
- Journal of Clinical Oncology. 36:TPS3120-TPS3120
- Publication Year :
- 2018
- Publisher :
- American Society of Clinical Oncology (ASCO), 2018.
-
Abstract
- TPS3120Background: Immune checkpoint inhibitor (ICI) containing regimens have significantly improved survival outcomes in first- and second-line non-small cell lung cancer (NSCLC). However, the maj...
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
biology
business.industry
Anti pd 1
Improved survival
medicine.disease
respiratory tract diseases
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
030220 oncology & carcinogenesis
PD-L1
Internal medicine
medicine
biology.protein
Biomarker (medicine)
In patient
Non small cell
Open label
Lung cancer
business
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........743dfaa27154a2c5c8c921940d9f9b08